The National Medical Products Administration has approved the issuance of a drug registration certificate, and the domestic Lraglutide has been approved for marketing, which means a new option for diabetic patients.
Liraglutide injection (trade name: Lirlupin) "suitable for adult type 2 diabetes patients for blood glucose control" was approved. According to introducing, liraglutide belongs to GLP-1 receptor agonist, GLP-1 products are relatively safe, is relatively mature, stable and safe target, in clinical mainly used to improve blood glucose control of adult type 2 diabetes, with blood sugar dependence promote insulin secretion, protect islet β cells, delay gastric emptying reduce appetite and other physiological functions.
Data show that the number of diabetes patients in China shows a continuous and rapid growth trend. Previously, liraglutide injection has been included in the National Guidelines for the Prevention and Management of Grassroots Diabetes (2022) and the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition).
As for the approval of domestic Lraglutide, Huadong Pharmaceutical said that it will further enrich the product line in the field of diabetes, and will continue to take diabetes medication as an important core field in the future, continue to increase the layout, and continue to promote the development and industrialization of new drugs under research and introduction.
The team also said that they have built a comprehensive and differentiated product pipeline of long-acting and multi-target global innovative drugs and biosimilar drugs around the GLP-1 targets. For example, the GLP-1R / GCGR / FGF21R long-acting three-target agonist DR10624 is in phase I clinical trials in New Zealand, Smegallutide injection is also in phase I clinical trials, and the global innovative small molecule oral GLP-1 receptor agonist TTP273 has completed phase II clinical trials.
It is worth mentioning that the World Health Organization's Expert Committee on the Selection and Use of Essential Medicines will reportedly meet this month to assess the efficacy of liraglutide and other broader weight-loss therapies, and the latest list of essential medicines will be released in September.
